According to filings with the U.S. Securities and Exchange Commission, FesariusTherapeutics has raised $20 Million in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Jefferson Life Sciences (JLS), Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation JJDC, Inc.), Empire State Development’s NY Ventures, and the American Society of Plastic Surgeons (ASPS)

About FesariusTherapeutics
FesariusTherapeutics is a commercial-stage medical technology company reimagining dermal repair. Its flagship product, DermiSphere is the first of its kind hydrogel Dermal Regeneration Template (hDRT), with a patented, dual-density collagen microarchitecture that is designed to facilitate cellular integration and vascularization to support wound healing. The device is 510(k)-cleared by FDA for wound management and commercially active across multiple U.S. hospital systems. The company is headquartered in New York and is advancing toward a pivotal clinical trial to support a planned future label expansion and Breakthrough Device Designation.

To learn more, visit https://www.fesariustherapeutics.com/
Linkedin: https://www.linkedin.com/company/fesariustherapeutics/

Contact:
Tom Roueche, Chief Executive Officer
https://www.linkedin.com/in/troueche/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.